IHC shows positive staining in paraffin-embedded human brain. Anti-Alpha Synuclein antibody was used at 1/250 dilution, followed by a HRP Polymer for Mouse IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | Alpha Synuclein |
| Synonyms | Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor (NACP); NACP; PARK1; SNCA |
| Location | Cytoplasm, Nucleus, Secreted, Synapse |
| Accession | P37840 |
| Clone Number | S-6514 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | IHC-P |
| Reactivity | Hu |
| Positive Sample | Human brain |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| IHC-P | 1:250 | Hu |
Background
α-Synuclein is a small soluble presynaptic protein of 140 amino acids with a molecular weight of approximately 14.5 kDa, encoded by the SNCA gene on human chromosome 4 and highly conserved among vertebrates. Its structure comprises three characteristic domains: an N-terminal lipid-binding domain (containing seven 11-amino-acid repeats that can form amphipathic α-helices), a central hydrophobic NAC region (responsible for fibrillar aggregation), and a negatively charged acidic C-terminal tail. Under physiological conditions, α-synuclein exists predominantly in the cytosol as a natively unfolded monomer, and through electrostatic binding to negatively charged phospholipids on synaptic vesicle membranes it undergoes a transition to an α-helical conformation, participating in the regulation of synaptic vesicle trafficking, clustering, exocytosis, and neurotransmitter release. Under pathological conditions, however, the protein misfolds into a β-sheet-rich structure, oligomerizes, and further forms amyloid fibrils, ultimately depositing within neurons as Lewy bodies—the shared pathological hallmark of "synucleinopathies" such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Notably, approximately 90% of α-synuclein in Lewy bodies is in the Ser129-phosphorylated form; although this modification is also regulated by neuronal activity under normal physiological conditions and participates in the fine-tuning of synaptic function, in the pathological state it becomes a widely recognized surrogate pathological marker due to the accumulation of aggregates. In addition, point mutations in the SNCA gene (such as A53T, A30P, and E46K) as well as gene duplication/triplication can cause familial early-onset Parkinson's disease, further confirming the central role of α-synuclein in the pathogenesis of neurodegenerative diseases.
Picture
Picture
Immunohistochemistry
Negative control: IHC shows negative staining in paraffin-embedded human kidney. Anti-Alpha Synuclein antibody was used at 1/250 dilution, followed by a HRP Polymer for Mouse IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
Negative control: IHC shows negative staining in paraffin-embedded human colon cancer. Anti-Alpha Synuclein antibody was used at 1/250 dilution, followed by a HRP Polymer for Mouse IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
